On the 27th, AZothBio and Prestige Biopharma IDC announced that they have signed a Memorandum of Understanding (MOU) to collaborate on research and business development.

Through this agreement, the two companies will leverage AZothBio's artificial intelligence (AI) and peptide technologies, along with Prestige Biopharma IDC's antibody expertise, to advance the research, development, and commercialization of new biotechnology. This collaboration aims to accelerate the progress of biotech innovations and strengthen their competitiveness in the global market.

Jae-Min Shin, CEO of AZothBio, emphasized, "The partnership between our two companies will play a crucial role in breaking new ground in biotechnology and providing new treatment options. We hope that our future R&D achievements will be commercialized and benefit many patients."

This MOU marks a significant milestone in combining the advanced technologies of both companies, fostering innovation in the biotechnology sector, and accelerating the development of new treatments.